| January 2000 | André Choulika and David Sourdive found Cellectis. |
|---|
| June 2000 | The company obtains licenses to six Pasteur Institute patent portfolios. The Pasteur Institute becomes a company shareholder. |
|---|
| November 2000 | Kaminvest Holding (Business Angel) becomes a company shareholder (equity increase of 3.8 million euros in two rounds). |
|---|
| November 2000 | The company moves into the Pasteur Institute's BioTop company incubator in Paris's 15th arrondissement. |
|---|
| August 2001 | Zentaris signs a license agreement with the company in the field of cancer. |
|---|
| October 2001 | GenOway signs a license agreement with the company in the field of animal models. |
|---|
| January 2002 | Constitution of the Scientific Advisory Board, chaired by Professor François Jacob, winner of the Nobel Prize for Medicine. |
|---|
| May 2002 | BankInvest Biomedical Venture, AGF Private Equity, Odyssée Venture and Edmond de Rothschild Investment Partners become company shareholders (equity increase of 8 million euros). |
|---|
| November 2002 | Pioneer Hi-Bred International - DuPont signs a license agreement with the company in the field of meganucleases applied to corn. |
|---|
| Mars 2003 | BASF Plant Science signs a license agreement with the company in the field of meganucleases applied to plant science. |
|---|
| June 2003 | Publication of an article in Nucleic Acids Research on the production of synthetic hybrid meganucleases, constituting the first step worldwide in implementation of this technology. |
|---|
| December 2003 | Regeneron Pharmaceuticals Inc. signs a license agreement with the company in the field of animal models. |
|---|
| February 2004 | The company moves its corporate office and labs from the BioTop incubator in Paris to the Biocitech campus in Romainville (in the Seine Saint-Denis county, just north of Paris). |
|---|
| April 2004 | Lexicon Genetics Inc. signs a license agreement with the company in the field of animal models. |
|---|
| June 2005 | BankInvest Biomedical Venture, AGF Private Equity, Odyssée Venture and Edmond de Rothschild Investment Partners make an additional 5.6 million euro investment in the company. |
|---|
| September 2005 | Biogen Idec signs an collaboration agreement with the company on the synthesis of custom meganucleases for use in protein production. |
|---|
| November 2005 | Publication of an article in Nucleic Acids Research on the production method for the custom meganucleases designed by the company. |
|---|
| December 2005 | TransKaryotic Therapies signs a license agreement with the company in the field of protein production. |
|---|
| January 2006 | Publication of an initial article in the Journal of Molecular Biology on the large-scale production of custom meganucleases (validating the company's commercial potential). |
|---|
| March 2006 | Publication in the Journal of Gene Medicine of an article on the first known experiment in in vivo meganuclease-based genome surgery (in the animal). |
|---|
| June 2006 | Bayer BioScience signs a collaboration agreement with the company on custom meganucleases in the field of plant science. |
|---|
| July 2006 | Lexicon Genetics Inc. signs a cross-licensing agreement with the company in the field of homologous recombination. |
|---|
| September 2006 | The company produces its first therapeutically-focused meganuclease recombination systems (MRSs). |
|---|
| November 2006 | The company achieves an annual production capacity of 8 MRSs. |
|---|
| December 2006 | Registration of its Document de Base with the AMF in the context of the Company's contemplated initial public offering on the Alternext market of Euronext Paris. |
|---|
| January 2007 | Publication of a Journal Nucleic Acids Research (NAR) article on artificial homing endonuclease. |
|---|
| 23 January 2007 | Launch of its initial public offering on the Alternext market of Euronext Paris. Guide price: between Eur 8.90 and Eur 10.25 per share |
|---|
| 6 February 2007 | Success of its initial public offering on the Alternext market of Euronext Paris. The offer price is set at Eur 10.25 per share
Demand from institutional investors was over 6 times the number of shares offered |
|---|
| 5 March 2007 | Full exercise of the greenshoe in the context of its initial public offering on the Alternext market of Euronext Paris. |
|---|
| 19 March 2007 | Cellectis S.A. announces the publication of a Current Gene Therapy article on Meganucleases and its Perspectives for Gene Therapy. |
|---|
| 3 April 2007 | Celonic sign a commercial license agreement following key milestone in meganuclease-mediated cell line engineering for biomanufacturing. |
|---|
| May 2007 | Cellectis grants GlaxoSmithKline a non-exclusive sub-license for its homologous recombination technology. |
|---|
| May 2007 | Cellectis announces the publication of a paper entitled "The C-terminal loop of the homing endonuclease I-CreI is essential for site recognition, DNA binding and cleavage" in the journal Nucleic Acids Research |
|---|
| May 2007 | Cellectis reaches key milestone in collaboration with Bayer Cropscience on uses of Meganuclease technology in plants. |
|---|
| 24 May 2007 | Cellectis will begin continuous trading on Alternext of Euronext Paris. |
|---|
| June 2007 | The Institut Pasteur and Cellectis announce the grant of a key European patent covering the use of homologous recombination in eukaryotes. |
|---|
| June 2007 | Cellectis S.A. wins a patent battle in the field of targeted recombination and gene correction. |
|---|
| June 2007 | Election of Professor Richard C. Mulligan to Cellectis' Board of Directors. |
|---|
| July 2007 | Cellectis announces the delivery of two meganucleases targeting the p53 gene in the framework of the NETSENSOR European program. |
|---|
| September 2007 | Cellectis announces the delivery of a meganuclease targeting the IL2RG gene responsible of a severe immunodeficiency linked to X chromosome (X-SCID) to Professor Alain Fisher's research group, Necker Hospital (INSERM U768). |
|---|
| September 2007 | Cellectis announces the presentation of results demonstrating the correction of an XP mutation in a patient's cell line by homologous gene targeting at the first French-German meeting on DNA repair, damage signaling and carcinogenesis in Toulouse. |
|---|
| October 2007 | Laboratoires Servier and Cellectis sign an agreement in the field of cell engineering. |
|---|
| October 2007 | Cellectis grants TransGenic a non-exclusive license to its homologous recombination technology. |
|---|
| November 2007 | Cellectis announces delivery of a meganuclease targeting the RAG1 gene (responsible for a severe immunodeficiency) to Professor Luigi Notarangelo's research group at the Children's Hospital Boston (USA). |
|---|
| December 2007 | Cellectis announces the publication of a key article in the Journal of Biological Chemistry. |
|---|
| December 2007 | Two significant nominations for Cellectis: Professor Alain Fischer joins the Scientific Advisory Board and Alain Godard joins the Board of Directors. |
|---|
| March 2008 | Cellectis sues Precision BioSciences for Infringement of its patents concerning Meganuclease technology. |
|---|
| April 2008 | Cellectis announces the publication of a paper entitled "Computer design of Obligate heterodimer meganucleases allow efficient cutting of custom DNA sequences", in the journal Nucleic Acids Research. |
|---|
| May 2008 | Cellectis sues Shionogi for infringement of its Patents concerning Homologous Recombination Technology. |
|---|
| June 2008 | Cellectis S.A. announces the inception of two subsidiaries: Cellectis BioResearch to develop and market research kits and Cellectis Genome Surgery to develop therapeutics |
|---|
| July 2008 | Cellectis and Regeneron sign an agreement over the use of homologous recombination technology. |
|---|
